MELISSA MERICLE: Open Payments
NPI 1760151328 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,769 in 52 payments from 18 companies in 2025. Trend: 2023 $668 · 2024 $873 · 2025 $1,769
Food & beverage: $1,669Education: $100
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $315 |
| Genmab U.S., Inc. | 9 | $287 |
| AstraZeneca Pharmaceuticals LP | 5 | $213 |
| ABBVIE INC. | 5 | $174 |
| Merck Sharp & Dohme LLC | 4 | $112 |
| Janssen Biotech, Inc. | 5 | $106 |
| SEAGEN INC. | 1 | $100 |
| Myriad Genetic Laboratories, Inc. | 1 | $87 |
| Novartis Pharmaceuticals Corporation | 3 | $73 |
| Lilly USA, LLC | 2 | $51 |
Products named: Tivdak, ZEJULA, ELAHERE, LYNPARZA, KEYTRUDA, MYRISK, JEMPERLI, VERZENIO.
Industry payments across AZ — which companies pay providers there.
